| pubmed-article:19819789 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C2003888 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C0022661 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C0948265 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C0002144 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C0041980 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:19819789 | lifeskim:mentions | umls-concept:C2745888 | lld:lifeskim |
| pubmed-article:19819789 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:19819789 | pubmed:dateCreated | 2009-10-12 | lld:pubmed |
| pubmed-article:19819789 | pubmed:abstractText | Allopurinol was administered to end-stage renal disease (ESRD) patients with elevated uric acid levels presenting with symptoms of gout and also had risk factors of metabolic syndrome. The primary aim of this pilot study was to examine the effects of lowering uric acid levels using allopurinol on lipoprotein markers of metabolic syndrome in patients. | lld:pubmed |
| pubmed-article:19819789 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19819789 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19819789 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19819789 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19819789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19819789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19819789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19819789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19819789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19819789 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19819789 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19819789 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:19819789 | pubmed:issn | 1308-0032 | lld:pubmed |
| pubmed-article:19819789 | pubmed:author | pubmed-author:BowdenRodney... | lld:pubmed |
| pubmed-article:19819789 | pubmed:author | pubmed-author:HartmanJessic... | lld:pubmed |
| pubmed-article:19819789 | pubmed:author | pubmed-author:WilsonRonald... | lld:pubmed |
| pubmed-article:19819789 | pubmed:author | pubmed-author:ShelmadineBri... | lld:pubmed |
| pubmed-article:19819789 | pubmed:author | pubmed-author:BeaversDaniel... | lld:pubmed |
| pubmed-article:19819789 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19819789 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:19819789 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19819789 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19819789 | pubmed:pagination | 385-9 | lld:pubmed |
| pubmed-article:19819789 | pubmed:dateRevised | 2010-6-15 | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:meshHeading | pubmed-meshheading:19819789... | lld:pubmed |
| pubmed-article:19819789 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19819789 | pubmed:articleTitle | The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. | lld:pubmed |
| pubmed-article:19819789 | pubmed:affiliation | Baylor University, School of Education, Waco, Texas, USA. | lld:pubmed |
| pubmed-article:19819789 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19819789 | lld:pubmed |
